| Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, ... Nature medicine 25 (3), 477-486, 2019 | 1153 | 2019 |
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma TF Cloughesy, K Yoshimoto, P Nghiemphu, K Brown, J Dang, S Zhu, ... PLoS medicine 5 (1), e8, 2008 | 672 | 2008 |
| Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme A Lai, A Tran, PL Nghiemphu, WB Pope, OE Solis, M Selch, E Filka, ... Journal of clinical oncology 29 (2), 142-148, 2011 | 562 | 2011 |
| Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin A Lai, S Kharbanda, WB Pope, A Tran, OE Solis, F Peale, WF Forrest, ... Journal of clinical oncology 29 (34), 4482-4490, 2011 | 531 | 2011 |
| Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain JC Lee, I Vivanco, R Beroukhim, JHY Huang, WL Feng, RM DeBiasi, ... PLoS medicine 3 (12), e485, 2006 | 423 | 2006 |
| Differential sensitivity of glioma-versus lung cancer–specific EGFR mutations to EGFR kinase inhibitors I Vivanco, HI Robins, D Rohle, C Campos, C Grommes, PL Nghiemphu, ... Cancer discovery 2 (5), 458-471, 2012 | 374 | 2012 |
| MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy WB Pope, A Lai, P Nghiemphu, P Mischel, TF Cloughesy Neurology 66 (8), 1258-1260, 2006 | 363 | 2006 |
| Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment1 WB Pope, HJ Kim, J Huo, J Alger, MS Brown, D Gjertson, V Sai, JR Young, ... Radiology 252 (1), 182-189, 2009 | 357 | 2009 |
| Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma JA Carrillo, A Lai, PL Nghiemphu, HJ Kim, HS Phillips, S Kharbanda, ... American Journal of Neuroradiology 33 (7), 1349-1355, 2012 | 318 | 2012 |
| Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience PL Nghiemphu, W Liu, Y Lee, T Than, C Graham, A Lai, RM Green, ... Neurology 72 (14), 1217-1222, 2009 | 281 | 2009 |
| Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy J Du, P Bernasconi, KR Clauser, DR Mani, SP Finn, R Beroukhim, ... Nature biotechnology 27 (1), 77-83, 2009 | 261 | 2009 |
| Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma WB Pope, A Lai, R Mehta, HJ Kim, J Qiao, JR Young, X Xue, J Goldin, ... American Journal of Neuroradiology 32 (5), 882-889, 2011 | 220 | 2011 |
| Probabilistic radiographic atlas of glioblastoma phenotypes BM Ellingson, A Lai, RJ Harris, JM Selfridge, WH Yong, K Das, WB Pope, ... American Journal of neuroradiology 34 (3), 533-540, 2013 | 219 | 2013 |
| Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma … A Lai, E Filka, B McGibbon, PL Nghiemphu, C Graham, WH Yong, ... International Journal of Radiation Oncology* Biology* Physics 71 (5), 1372-1380, 2008 | 208 | 2008 |
| Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma TF Cloughesy, J Landolfi, DJ Hogan, S Bloomfield, B Carter, CC Chen, ... Science translational medicine 8 (341), 341ra75-341ra75, 2016 | 201 | 2016 |
| Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter … BM Ellingson, HJ Kim, DC Woodworth, WB Pope, JN Cloughesy, ... Radiology 271 (1), 200-210, 2014 | 188 | 2014 |
| Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas BJ Fueger, J Czernin, T Cloughesy, DH Silverman, CL Geist, MA Walter, ... Journal of Nuclear Medicine 51 (10), 1532-1538, 2010 | 186 | 2010 |
| Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study WB Pope, XJ Qiao, HJ Kim, A Lai, P Nghiemphu, X Xue, BM Ellingson, ... Journal of neuro-oncology 108, 491-498, 2012 | 184 | 2012 |
| Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis LT McGillicuddy, JA Fromm, PE Hollstein, S Kubek, R Beroukhim, ... Cancer cell 16 (1), 44-54, 2009 | 180 | 2009 |
| Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma L Nayak, AM Molinaro, K Peters, JL Clarke, JT Jordan, J de Groot, ... Clinical Cancer Research 27 (4), 1048-1057, 2021 | 177 | 2021 |
